Merck Manual

Please confirm that you are a health care professional

Vaccination Program for Commercial Layers a

Vaccination Program for Commercial Layers a

Age

Vaccine

Route

Type

1 day

Marek’s disease

SC

Turkey herpesvirus and SB-1

14 –21 days

Newcastle/infectious bronchitis

Water

B1/Mass

14–21 days

Infectious bursal disease

Water

Intermediate

5 wk

Newcastle/infectious bronchitis

Water or coarse spray

B1/Mass

8–10 wk

Newcastle/infectious bronchitis

Water or coarse spray

B1 or LaSota/Mass

10–12 wk

Encephalomyelitis

Wing web

Live, chick-embryo origin

10–12 wk

Fowlpox

Wing web

Modified live

10–12 wk

Laryngotracheitis

Intraocular

Modified live

10–14 wk

Mycoplasma gallisepticumb

Intraocular or spray

Mild live strain

or 18 wk

Parenteral

Inactivated

12–14 wk

Newcastle/infectious bronchitis

Water or aerosol

B1 or LaSota/Mass

16–18 wk

Newcastle/infectious bronchitis

Water or aerosol

B1 or LaSota/Mass

Every 60–90 days or 18 wk

Newcastle/infectious bronchitis

Parenteral

Inactivated

a This is an example of a vaccination program. Individual programs are highly variable and reflect local conditions, disease prevalence, severity of challenge, and individual preferences.

b The use of M gallisepticum vaccine is regulated or prohibited in some states. SB-1 or MDV301 may be combined with turkey herpesvirus in some areas, or Rispens strain may be used in high-challenge areas. Vaccination for infectious bursal disease, laryngotracheitis, and fowlpox depends on local requirements. Other strains of infectious bronchitis (Connecticut, Arkansas 99, Florida 88, etc) are included in some areas. M gallisepticum and Haemophilus gallinarum (coryza) are used only on infected, multiage premises in some areas.